Anton Sterner1,2, Kristoffer Derwinger3,4, Caroline Staff5, Hanna Nilsson3,4, Eva Angenete3,4. 1. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. anton.sterner@vgregion.se. 2. Region Västra Götaland, Sahlgrenska University Hospital, Department Of Surgery, Gothenburg, Sweden. anton.sterner@vgregion.se. 3. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. 4. Region Västra Götaland, Sahlgrenska University Hospital, Department Of Surgery, Gothenburg, Sweden. 5. Department of Surgery, Capio S:t Görans Sjukhus, Stockholm, Sweden.
Abstract
PURPOSE: Anal cancer is a mainly treated with chemoradiotherapy. A small number of patients undergo salvage surgery. There are few published studies investigating quality of life and functional outcome after treatment for anal cancer. The aim of this review was to explore the literature and identify areas for further research. METHODS: A search was conducted in Medline using MESH terms related to anal cancer and quality of life. Two investigators selected and reviewed articles based on titles and abstracts. Three investigators read and reviewed the included articles and collected relevant data. The included articles were evaluated using the minimum standard checklist, and key findings were summarised in a chart. RESULTS: Some 15 articles, and a total of 802 patients, were deemed eligible. The results differed slightly among the studies. The incidence of symptoms such as fatigue, nausea, insomnia and appetite loss was higher than among healthy volunteers. Bowel function, urinary function and sexual function were negatively affected. Some studies found that, compared with the normal population, anal cancer survivors scored clinically significant worse in the functional scales in QLQ-C30. CONCLUSION: In conclusion, it is apparent that several functional problems affect the quality of life of patients with anal cancer. There are few studies which have investigated quality of life after treatment for anal cancer. Interventions to address issues related to anal cancer treatment may improve long-term quality of life in this patient group. TRIAL REGISTRATION: CRD42017059787.
PURPOSE:Anal cancer is a mainly treated with chemoradiotherapy. A small number of patients undergo salvage surgery. There are few published studies investigating quality of life and functional outcome after treatment for anal cancer. The aim of this review was to explore the literature and identify areas for further research. METHODS: A search was conducted in Medline using MESH terms related to anal cancer and quality of life. Two investigators selected and reviewed articles based on titles and abstracts. Three investigators read and reviewed the included articles and collected relevant data. The included articles were evaluated using the minimum standard checklist, and key findings were summarised in a chart. RESULTS: Some 15 articles, and a total of 802 patients, were deemed eligible. The results differed slightly among the studies. The incidence of symptoms such as fatigue, nausea, insomnia and appetite loss was higher than among healthy volunteers. Bowel function, urinary function and sexual function were negatively affected. Some studies found that, compared with the normal population, anal cancer survivors scored clinically significant worse in the functional scales in QLQ-C30. CONCLUSION: In conclusion, it is apparent that several functional problems affect the quality of life of patients with anal cancer. There are few studies which have investigated quality of life after treatment for anal cancer. Interventions to address issues related to anal cancer treatment may improve long-term quality of life in this patient group. TRIAL REGISTRATION: CRD42017059787.
Authors: Ramez Kouzy; Joseph Abi Jaoude; Daniel Lin; Molly B El Alam; Bruce D Minsky; Eugene J Koay; Prajnan Das; Emma B Holliday; Ann H Klopp; Lauren E Colbert; Cullen M Taniguchi Journal: JCO Oncol Pract Date: 2020-07-01
Authors: Praveen D Chatani; Dana A Dominguez; John G Aversa; Jeremy L Davis; Jonathan M Hernandez; Lily L Lai; Andrew M Blakely Journal: Surg Oncol Date: 2021-03-31 Impact factor: 2.388
Authors: Christina Sauter; Jan C Peeken; Kai Borm; Christian Diehl; Stefan Münch; Stephanie E Combs; Hendrik Dapper Journal: Sci Rep Date: 2022-03-15 Impact factor: 4.379
Authors: Daniel R Principe; Jose L Cataneo; Kaytlin E Timbers; Regina M Koch; Klara Valyi-Nagy; Anders Mellgren; Ajay Rana; Gerald Gantt Journal: BMC Cancer Date: 2022-06-24 Impact factor: 4.638
Authors: Martin P Nilsson; Erik D Nilsson; Anders Johnsson; Otilia Leon; Adalsteinn Gunnlaugsson; Jonas Scherman Journal: Radiat Oncol Date: 2020-05-27 Impact factor: 3.481